A study of Moderna Inc.’s coronavirus vaccine issued in the New England Journal of Medicine reported the candidate has the potential to produce durable immunity to the virus.
In the Phase 1 trial, led by the National Institute of Allergy and Infectious Diseases (NIAID), participants across all age groups retained high levels of neutralizing antibodies through 119 days after the first vaccination, Moderna said.
In recent days, the debate surrounding instances of whale or shark species attacking humans has…
Civil Protection spokesperson reported that a 35-year-old young man passed away today in a road accident…
The private radio station IFM declared the temporary suspension of the Emission Impossible program hosted…
The Facebook page of Slovak Prime Minister Robert Fico revealed on Wednesday that the official…
Speaking to Tunisie Numérique, President of the Tunisian Union of Agriculture and Fisheries Noureddine Ben…
Yesterday, Tuesday, a meeting took place at the headquarters of the National Establishment for the…
This website uses cookies.